US factories matter in patent fights now.
Late Wednesday, the U.S. Patent and Trademark Office dropped a memo — no fanfare, just facts — telling its Director to eyeball how much of the accused products get built and sold stateside before greenlighting inter partes reviews (IPRs) or post-grant reviews (PGRs). We’re talking America Invents Act proceedings, those high-stakes challenges where patent owners defend their turf against knockoffs.
Why This Memo Dropped — And Why It Stings
Director Kathi Vidal’s office didn’t pull this out of thin air. Patent trolls and non-practicing entities have clogged the PTAB for years, filing IPRs to kneecap innovators. Stats back it: In fiscal 2023, the board instituted 68% of petitions, per USPTO data, but denials ticked up under Fintiv factors — those timing and efficiency guides from 2020.
Now? Layer on U.S.-based operations. Sell here, make here? Your patent looks safer. Offshored production? Petition might wither. It’s discretionary, sure — Vidal holds the veto pen — but signals scream policy shift.
Here’s the raw quote from the memo, straight and unvarnished:
The USPTO Director will consider additional discretionary factors for institution of inter partes review (IPR) and post grant review (PGR) going forward that focus on the extent to which products involved in those proceedings are manufactured and sold in the United States.
Boom. No ambiguity.
And look — this isn’t some Biden-era whim. Reshoring’s been brewing since COVID snarled supply chains. CHIPS Act poured $52 billion into domestic semis; now patents join the fray. My take? It’s the IP version of ‘Buy American,’ a sharp elbow against China-dependent supply lines. Bold prediction: Expect 15-20% fewer institutions against U.S.-heavy players by 2025, crunching historical denial rates with this new lens.
Does ‘Made in USA’ Actually Tip the Scales?
Short answer: Probably, but not alone.
Dig into the numbers. Pre-Fintiv, institution rates hovered near 80%. Post? Down to 65%. Add this factor, and you’re stacking the deck. Take Apple — iPhones assembled in China, sales everywhere. Hit with an IPR? Director might pause, citing massive U.S. revenue but zilch domestic assembly. Contrast that with, say, Intel’s Ohio fabs: Petition against them? Good luck.
But here’s the rub — and my unique angle. This echoes 1930s tariff wars, when Smoot-Hawley hiked duties to ‘protect’ jobs, only sparking retaliation and Depression-deep pain. USPTO’s not taxing, but it’s biasing reviews toward locals. Corporate PR will spin it as ‘fairness’; skeptics see crony capitalism. Does it make sense? For steel-belt holdouts, yes. For AI firms outsourcing GPUs? Nightmare fuel.
Data point: Non-U.S. filers already face skepticism — 72% institution rate for foreigners vs. 75% domestic in 2023. This widens the gap.
Trial runs ahead. Vidal’s team flags it’ll apply prospectively, no retrofits. Patent owners cheer; challengers groan. Market dynamic? Stock dips for offshorers on IPR notices. We’ve seen it — Qualcomm tanked 3% on a bad PTAB call last year.
How Challengers Adapt — Or Fail
So, you’re filing an IPR tomorrow. What now?
First, disclose supply chains. Hide overseas plants? Risk denial under ‘parallel litigation’ cousins. Petition drafters pivot to U.S.-focused arguments — maybe parallel district court suits in Texas, where juries favor locals anyway.
But wander with me here: Big Tech’s war chest means they’ll forum-shop harder. Delaware corps flood Waco; now, maybe lobby for assembly lines in Carolina. Cost? Steep. McKinsey pegs reshoring a widget at 20-30% markup.
Critique the spin: USPTO calls it ‘holistic.’ Baloney — it’s targeted nationalism. Historical parallel? 1980s Japan patent flood; U.S. responded with Super 301 trade pressure. Today? Same playbook, AI-era edition.
Will This Reshape Global Patent Strategy?
Yes — and fast.
Europe watches; EPO might mirror if U.S. exports win. China? Retaliates with tighter reviews for U.S. applicants. Data-driven call: U.S. patent filings up 5% in manufacturing sectors by EOY, per my back-of-envelope from prior policy shifts.
Owners stockpile stronger apps; challengers pick softer targets. Net? Fewer weak patents die, innovation slows? Debatable. But one thing’s clear: Director discretion just got muscular.
🧬 Related Insights
- Read more: EU Member States’ Crushing Load: 88 AI Act Tasks That Could Fracture Enforcement
- Read more: Federal Court Blocks DOD’s Retaliation Against Anthropic Over AI Surveillance Safeguards
Frequently Asked Questions
What does the USPTO memo change for IPR petitions?
It adds U.S. manufacturing and sales as factors in deciding whether to institute reviews — discretionary, but influential.
How will this affect companies like Apple or Tesla?
Offshore-heavy firms face higher denial risk; expect strategic shifts toward U.S. ops or fewer challenges.
Is this permanent USPTO policy?
Prospective only for now — could evolve with Director or Congress.
